Trial Profile
A Phase 1 Study of AZD2171 and WBRT in Patients With Brain Metastases.
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 12 Mar 2013
Price :
$35
*
At a glance
- Drugs Cediranib (Primary)
- Indications Cancer metastases; Non-small cell lung cancer
- Focus Adverse reactions
- 07 Mar 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 08 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 28 Nov 2012 Planned number of patients changed from 12 to 18 as reported by ClinicalTrials.gov.